Soykan Agar 1*, Barbaros Akkurt 2
Pancreatic Ductal Adenocarcinoma (PDAC) presents a challenging prognosis, attributed to its aggressive nature, delayed diagnosis, and
the absence of effective therapeutic options for advanced stages. The significant mortality associated with PDAC prompted investigations
into alternative factors contributing to its treatment. Liver X receptors, specifically LXRα and LXRβ, are nuclear receptors that govern the
transcription of genes related to cholesterol, glucose, lipid metabolism, and inflammatory responses. Recently, LXRs have emerged as po-
tential targets for PDAC, with LXR ligands demonstrating anti-proliferative effects in various cancer types, particularly pancreatic cancer.
This comprehensive in silico research study delves into the investigation of inhibitory ligands for LXRα and LXRβ, presumed to play a prog-
nostic role in PDAC. Employing techniques such as molecular docking, molecular dynamics, and ADME, the study aimed to characterize the
inhibition of these receptors. The findings highlight Baicalein as a versatile drug, exhibiting superior suppression of both LXRα and LXRβ
receptors, while β-Sitosterol emerges as the most efficient inhibitor of LXRβ. Further in vitro and in vivo analysis is deemed necessary to
validate the potential of these natural products for pancreatic cancer treatment.
Pancreatic Ductal Adenocarcinoma (PDAC) presents a challenging prognosis, attributed to its aggressive nature, delayed diagnosis, and
the absence of effective therapeutic options for advanced stages. The significant mortality associated with PDAC prompted investigations
into alternative factors contributing to its treatment. Liver X receptors, specifically LXRα and LXRβ, are nuclear receptors that govern the
transcription of genes related to cholesterol, glucose, lipid metabolism, and inflammatory responses. Recently, LXRs have emerged as po-
tential targets for PDAC, with LXR ligands demonstrating anti-proliferative effects in various cancer types, particularly pancreatic cancer.
This comprehensive in silico research study delves into the investigation of inhibitory ligands for LXRα and LXRβ, presumed to play a prog-
nostic role in PDAC. Employing techniques such as molecular docking, molecular dynamics, and ADME, the study aimed to characterize the
inhibition of these receptors. The findings highlight Baicalein as a versatile drug, exhibiting superior suppression of both LXRα and LXRβ
receptors, while β-Sitosterol emerges as the most efficient inhibitor of LXRβ. Further in vitro and in vivo analysis is deemed necessary to
validate the potential of these natural products for pancreatic cancer treatment.
Published Date: 2024-02-13; Received Date: 2024-01-23
